India, July 30 -- Clinical-stage biopharmaceutical company Oryzon Genomics, S.A. (ORY.MC) on Wednesday reported results for the first half of 2025, posting a net loss of $3.44 million, or $0.03 per share, compared to a loss of $2.57 million, or $0.02 per share, in the same period last year.
For the second quarter, the company reported a net loss of $1.72 million, compared to $1.49 million a year ago.
The company said that since last December, the company has secured $61 million in funding, including $35.2 million from a successful capital raise completed in April through a straight equity issuance with no warrants attached.
"Our successful €30 million capital raise, executed under extraodinarily challenging market conditions, repre...